演讲题目
实体肿瘤治疗领域的国际进展

刘诚

Dr. Cheng Liu (“Dr. Liu”), is the founder and has served as the president and chief executive officer of Eureka since May 2006. Prior to that, Dr. Liu was a principal scientist in antibody drug discovery at Chiron Corporation (now integrated into Novartis), where he championed the anti-CSF1 antibody program for the treatment of bone metastases to human clinical trials. He is the inventor of multiple issued US patents in drug discovery. In 2007, he was awarded a Special US Congressional Recognition for his contributions to improving human health.Dr. Liu received his bachelor’s degree in cell biology and genetics from Peking University ( 北京大學 ) in the PRC in July 1988 and a Ph.D. in molecular cell biology from the University of California, Berkeley in the United States in May 1996.